The objectives of the review were to address the following questions:
- How effective is infliximab as a second- or third-line treatment for severe active Crohn's disease in adults who have not responded to conventional treatment?
- How effective is infliximab at reducing the number of draining fistulae in adult patients with fistulising Crohn's disease who have not responded to conventional treatment?
- What is the frequency and severity of adverse effects associated with the use of infliximab?
- What adverse events are associated with repeated treatment with infliximab?
- How cost-effective is infliximab for the above indications compared with standard practice?